Puma Biotechnology Showcases Pipeline Progress and NERLYNX Commercial Updates in New Corporate Presentation

Reuters11-18

Puma Biotechnology Showcases Pipeline Progress and NERLYNX Commercial Updates in New Corporate Presentation

Puma Biotechnology Inc. presented updates on the commercialization of NERLYNX®, including recent performance metrics and distribution network information. The company reported net revenue of $51.9 million in Q3 2025, reflecting an approximately 8% decrease compared to Q3 2024, but a 6% increase from Q2 2025. Inventory changes amounted to $3.1 million in Q3 2025, up from $0.7 million in Q3 2024 and -$1.3 million in Q2 2025. The number of bottles distributed in Q3 2025 was 2,723, compared to 2,949 in Q3 2024 and 2,608 in Q2 2025. The percentage of patients starting NERLYNX® at a reduced dose continued to fluctuate, with the latest figures indicating varying adoption rates. The company also provided a regional update on regulatory approvals and commercial launches, highlighting recent progress in Australia, Southeast Asia, and other markets. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Puma Biotechnology Inc. published the original content used to generate this news brief on November 17, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2584677769?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-18 06:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584677769","market":"us","top_or_hot":-1,"title":"Puma Biotechnology Showcases Pipeline Progress and NERLYNX Commercial Updates in New Corporate Presentation","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Puma Biotechnology Showcases Pipeline Progress and NERLYNX Commercial Updates in New Corporate Presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/PBYI\">Puma Biotechnology Inc</a>. presented updates on the commercialization of NERLYNX®, including recent performance metrics and distribution network information. The company reported net revenue of $51.9 million in Q3 2025, reflecting an approximately 8% decrease compared to Q3 2024, but a 6% increase from <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2025. Inventory changes amounted to $3.1 million in Q3 2025, up from $0.7 million in Q3 2024 and -$1.3 million in Q2 2025. The number of bottles distributed in Q3 2025 was 2,723, compared to 2,949 in Q3 2024 and 2,608 in Q2 2025. The percentage of patients starting NERLYNX® at a reduced dose continued to fluctuate, with the latest figures indicating varying adoption rates. The company also provided a regional update on regulatory approvals and commercial launches, highlighting recent progress in Australia, Southeast Asia, and other markets. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Puma Biotechnology Inc. published the original content used to generate this news brief on November 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Puma Biotechnology Showcases Pipeline Progress and NERLYNX Commercial Updates in New Corporate Presentation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPuma Biotechnology Showcases Pipeline Progress and NERLYNX Commercial Updates in New Corporate Presentation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-18 06:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Puma Biotechnology Showcases Pipeline Progress and NERLYNX Commercial Updates in New Corporate Presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/PBYI\">Puma Biotechnology Inc</a>. presented updates on the commercialization of NERLYNX®, including recent performance metrics and distribution network information. The company reported net revenue of $51.9 million in Q3 2025, reflecting an approximately 8% decrease compared to Q3 2024, but a 6% increase from <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2025. Inventory changes amounted to $3.1 million in Q3 2025, up from $0.7 million in Q3 2024 and -$1.3 million in Q2 2025. The number of bottles distributed in Q3 2025 was 2,723, compared to 2,949 in Q3 2024 and 2,608 in Q2 2025. The percentage of patients starting NERLYNX® at a reduced dose continued to fluctuate, with the latest figures indicating varying adoption rates. The company also provided a regional update on regulatory approvals and commercial launches, highlighting recent progress in Australia, Southeast Asia, and other markets. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Puma Biotechnology Inc. published the original content used to generate this news brief on November 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PBYI","symbol_name":"Puma Biotechnology Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL4H6Yz:1","article_id":"2584677769","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584677769","pubTimestamp":1763418812,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Puma Biotechnology Inc. presented updates on the commercialization of NERLYNX, including recent performance metrics and distribution network information. The company reported net revenue of $51.9 million in Q3 2025, reflecting an approximately 8% decrease compared to Q3 2024, but a 6% increase from Q2 2025. Inventory changes amounted to $3.1 million in Q3 2025, up from $0.7 million in Q3 2024 and -$1.3 million in Q2 2025. The number of bottles distributed in Q3 2025 was 2,723, compared to 2,949 in Q3 2024 and 2,608 in Q2 2025. The percentage of patients starting NERLYNX at a reduced dose continued to fluctuate, with the latest figures indicating varying adoption rates. The company also provided a regional update on regulatory approvals and commercial launches, highlighting recent progress in Australia, Southeast Asia, and other markets. You can access the full presentation through the link below.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PBYI":"Puma Biotechnology Inc","BK4139":"生物科技"},"translate_title":"Puma Biotechnology在新的公司演示中展示了管道进展和NERLYNX商业更新","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PBYI":0.9},"content_text":"Puma Biotechnology Showcases Pipeline Progress and NERLYNX Commercial Updates in New Corporate Presentation\n    \n\nPuma Biotechnology Inc. presented updates on the commercialization of NERLYNX®, including recent performance metrics and distribution network information. The company reported net revenue of $51.9 million in Q3 2025, reflecting an approximately 8% decrease compared to Q3 2024, but a 6% increase from Q2 2025. Inventory changes amounted to $3.1 million in Q3 2025, up from $0.7 million in Q3 2024 and -$1.3 million in Q2 2025. The number of bottles distributed in Q3 2025 was 2,723, compared to 2,949 in Q3 2024 and 2,608 in Q2 2025. The percentage of patients starting NERLYNX® at a reduced dose continued to fluctuate, with the latest figures indicating varying adoption rates. The company also provided a regional update on regulatory approvals and commercial launches, highlighting recent progress in Australia, Southeast Asia, and other markets. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Puma Biotechnology Inc. published the original content used to generate this news brief on November 17, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2584677769","isCrawlerRequest":true}